Abstract
Retinal gene therapy has proven safe and at least partially successful in clinical trials and in numerous animal models. Gene therapy requires characterization of the progression of the disease and understanding of its genetic cause. Testing gene therapies usually requires an animal model that recapitulates the key features of the human disease, though photoreceptors and cells of the retinal pigment epithelium produced from patient-derived stem cells may provide an alternative test system for retinal gene therapy. Gene therapy also requires a delivery system that introduces the therapeutic gene to the correct cell type and does not cause unintended damage to the tissue. Current systems being tested in the eye are nanoparticles, pseudotyped lentiviruses, and adeno-associated virus (AAV) of various serotypes. Here, we describe the techniques of AAV vector design as well as the in vivo and ex vivo tests necessary for assessing the efficacy of retinal gene therapy to treat retinal degeneration caused by mutations in the rhodopsin gene.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Athanasiou D, Aguila M, Bevilacqua D et al (2013) The cell stress machinery and retinal degeneration. FEBS Lett 587:2008–2017
Mendes HF, van der Spuy J, Chapple JP et al (2005) Mechanisms of cell death in rhodopsin retinitis pigmentosa: implications for therapy. Trends Mol Med 11:177–185
Komeima K, Rogers BS, Lu L et al (2006) Antioxidants reduce cone cell death in a model of retinitis pigmentosa. Proc Natl Acad Sci U S A 103:11300–11305
Bowne SJ, Sullivan LS, Koboldt DC et al (2011) Identification of disease-causing mutations in autosomal dominant retinitis pigmentosa (adRP) using next-generation DNA sequencing. Invest Ophthalmol Vis Sci 52:494–503
Rossmiller B, Mao H, Lewin AS (2012) Gene therapy in animal models of autosomal dominant retinitis pigmentosa. Mol Vis 18:2479–2496
Cideciyan AV, Hauswirth WW, Aleman TS et al (2009) Human RPE65 gene therapy for Leber congenital amaurosis: persistence of early visual improvements and safety at 1 year. Hum Gene Ther 20:999–1004
Cideciyan AV, Hauswirth WW, Aleman TS et al (2009) Vision 1 year after gene therapy for Leber’s congenital amaurosis. N Engl J Med 361:725–727
Hauswirth WW, Aleman TS, Kaushal S et al (2008) Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial. Hum Gene Ther 19:979–990
Al-Saikhan FI (2013) The gene therapy revolution in ophthalmology. Saudi J Ophthalmol 27:107–111
Alexander JJ, Hauswirth WW (2008) Adeno-associated viral vectors and the retina. Adv Exp Med Biol 613:121–128
Trapani I, Colella P, Sommella A et al (2014) Effective delivery of large genes to the retina by dual AAV vectors. EMBO Mol Med 6:194–211
Ghosh A, Yue Y, Duan D (2011) Efficient transgene reconstitution with hybrid dual AAV vectors carrying the minimized bridging sequences. Hum Gene Ther 22:77–83
Ghosh A, Yue Y, Lai Y et al (2008) A hybrid vector system expands adeno-associated viral vector packaging capacity in a transgene-independent manner. Mol Ther 16:124–130
Ghosh A, Yue Y, Duan D (2006) Viral serotype and the transgene sequence influence overlapping adeno-associated viral (AAV) vector-mediated gene transfer in skeletal muscle. J Gene Med 8:298–305
Greenwald DL, Cashman SM, Kumar-Singh R (2013) Mutation-independent rescue of a novel mouse model of Retinitis Pigmentosa. Gene Ther 20:425–434
Mao H, Gorbatyuk MS, Rossmiller B et al (2012) Long-term rescue of retinal structure and function by rhodopsin RNA replacement with a single adeno-associated viral vector in P23H RHO transgenic mice. Hum Gene Ther 23:356–366
Millington-Ward S, Chadderton N, O’Reilly M et al (2011) Suppression and replacement gene therapy for autosomal dominant disease in a murine model of dominant retinitis pigmentosa. Mol Ther 19:642–649
Mussolino C, Sanges D, Marrocco E et al (2011) Zinc-finger-based transcriptional repression of rhodopsin in a model of dominant retinitis pigmentosa. EMBO Mol Med 3:118–128
McCarty DM (2008) Self-complementary AAV vectors; advances and applications. Mol Ther 16:1648–1656
Kay CN, Ryals RC, Aslanidi GV et al (2013) Targeting photoreceptors via intravitreal delivery using novel, capsid-mutated AAV vectors. PLoS One 8:e62097
Goto Y, Peachey NS, Ripps H et al (1995) Functional abnormalities in transgenic mice expressing a mutant rhodopsin gene. Invest Ophthalmol Vis Sci 36:62–71
Pennesi ME, Michaels KV, Magee SS et al (2012) Long-term characterization of retinal degeneration in rd1 and rd10 mice using spectral domain optical coherence tomography. Invest Ophthalmol Vis Sci 53:4644–4656
Umino Y, Solessio E, Barlow RB (2008) Speed, spatial, and temporal tuning of rod and cone vision in mouse. J Neurosci 28:189–198
Prusky GT, Alam NM, Beekman S et al (2004) Rapid quantification of adult and developing mouse spatial vision using a virtual optomotor system. Invest Ophthalmol Vis Sci 45:4611–4616
Mueller C, Flotte TR (2008) Clinical gene therapy using recombinant adeno-associated virus vectors. Gene Ther 15:858–863
Grieger JC, Samulski RJ (2012) Adeno-associated virus vectorology, manufacturing, and clinical applications. Methods Enzymol 507:229–254
Flannery JG, Zolotukhin S, Vaquero MI et al (1997) Efficient photoreceptor-targeted gene expression in vivo by recombinant adeno-associated virus. Proc Natl Acad Sci U S A 94:6916–6921
Wang L, Blouin V, Brument N et al (2011) Production and purification of recombinant adeno-associated vectors. Methods Mol Biol 807:361–404
Zolotukhin S, Potter M, Zolotukhin I et al (2002) Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors. Methods 28:158–167
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer Science+Business Media New York
About this protocol
Cite this protocol
Rossmiller, B.P., Ryals, R.C., Lewin, A.S. (2015). Gene Therapy to Rescue Retinal Degeneration Caused by Mutations in Rhodopsin. In: Jastrzebska, B. (eds) Rhodopsin. Methods in Molecular Biology, vol 1271. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-2330-4_25
Download citation
DOI: https://doi.org/10.1007/978-1-4939-2330-4_25
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-2329-8
Online ISBN: 978-1-4939-2330-4
eBook Packages: Springer Protocols